Headlands Technologies LLC Acquires Shares of 55,106 Zoetis Inc. $ZTS

Headlands Technologies LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 55,106 shares of the company’s stock, valued at approximately $3,960,000.

A number of other hedge funds have also recently modified their holdings of the stock. BlackRock Inc. raised its position in Zoetis by 10.8% during the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after acquiring an additional 3,845,869 shares in the last quarter. J. Stern & Co. LLP grew its stake in shares of Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after purchasing an additional 23,877,416 shares during the period. State Street Corp grew its stake in shares of Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock worth $2,490,845,000 after purchasing an additional 149,382 shares during the period. Geode Capital Management LLC increased its holdings in shares of Zoetis by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after purchasing an additional 189,235 shares in the last quarter. Finally, Deutsche Bank AG lifted its stake in shares of Zoetis by 5.8% in the 2nd quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock valued at $420,506,000 after purchasing an additional 319,709 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on ZTS shares. Stifel Nicolaus dropped their price target on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a research report on Thursday, August 20th. Zacks Research downgraded shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Citigroup dropped their price objective on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Morgan Stanley set a $85.00 target price on shares of Zoetis in a research note on Friday, August 7th. Finally, Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $107.43.

Zoetis Stock Performance

Shares of Zoetis stock opened at $77.45 on Monday. The firm has a market cap of $32.00 billion, a PE ratio of 12.76, a price-to-earnings-growth ratio of 1.80 and a beta of 0.73. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a 52 week low of $71.00 and a 52 week high of $156.49. The business’s fifty day simple moving average is $75.57 and its 200-day simple moving average is $95.40.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s revenue for the quarter was down .2% on a year-over-year basis. During the same period last year, the business earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.